Antitrust laws, also referred to as “competition laws”, are statutes developed by the United States Government to protect consumers from predatory business practices. They ensure that fair competition exists in an open-market economy.
Antitrust litigation in the pharmaceutical industry encompasses potential class-action lawsuits reflecting anti-competitive conduct by innovator (branded) and generic pharmaceutical manufacturers. Some of the practices observed relate to terms and results of strategic alliances between key players that have the potential to create a market monopoly, thereby impacting the availability of lower-cost products (generic versions of innovator pharmaceuticals), including their pricing, marketing, and distribution procedures.
Our industry expert consultants are senior leaders from the pharmaceutical industry with practical experience in all aspects of pharmaceutical antitrust litigation. Our team has delivered pre and post-Loss of Exclusivity strategies, generic product launch readiness for authorized generics, and Paragraph IV ANDA submission and approvals. It has also advised on commercial operations, manufacturing, regulatory adherence, inventory management, distribution channels, pricing strategies, direct and indirect payor strategies, product life-cycle management and management of Loss of Exclusivity (LOE).
